Evolus’ (EOLS) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Evolus (NASDAQ:EOLS) in a research note published on Thursday morning,Benzinga reports. They currently have a $27.00 target price on the stock. HC Wainwright also issued estimates for Evolus’ FY2026 earnings at $0.41 EPS, FY2027 earnings at $1.06 EPS, FY2028 earnings at $2.20 EPS and FY2029 earnings at $3.60 EPS.

EOLS has been the topic of several other research reports. Barclays boosted their target price on shares of Evolus from $22.00 to $25.00 and gave the stock an “overweight” rating in a report on Wednesday, March 5th. Needham & Company LLC restated a “buy” rating and set a $22.00 price objective on shares of Evolus in a research report on Wednesday.

Evolus Trading Down 9.3 %

Shares of Evolus stock opened at $9.41 on Thursday. The company has a debt-to-equity ratio of 20.58, a quick ratio of 2.23 and a current ratio of 2.47. The company has a fifty day moving average of $12.98 and a 200 day moving average of $13.37. The company has a market capitalization of $598.35 million, a P/E ratio of -10.34 and a beta of 0.97. Evolus has a fifty-two week low of $8.67 and a fifty-two week high of $17.82.

Insider Buying and Selling

In other news, CMO Tomoko Yamagishi-Dressler sold 4,536 shares of Evolus stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $13.26, for a total value of $60,147.36. Following the transaction, the chief marketing officer now directly owns 95,671 shares in the company, valued at approximately $1,268,597.46. This trade represents a 4.53 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider David Moatazedi sold 6,251 shares of the business’s stock in a transaction on Thursday, March 27th. The stock was sold at an average price of $12.40, for a total value of $77,512.40. Following the completion of the transaction, the insider now directly owns 508,619 shares of the company’s stock, valued at approximately $6,306,875.60. The trade was a 1.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 60,575 shares of company stock valued at $794,369. Insiders own 6.10% of the company’s stock.

Hedge Funds Weigh In On Evolus

Several institutional investors and hedge funds have recently added to or reduced their stakes in EOLS. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Evolus by 3.6% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,451 shares of the company’s stock valued at $347,000 after buying an additional 1,094 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its stake in shares of Evolus by 10.6% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 13,426 shares of the company’s stock worth $148,000 after acquiring an additional 1,291 shares in the last quarter. Rhumbline Advisers lifted its position in Evolus by 2.2% during the fourth quarter. Rhumbline Advisers now owns 80,149 shares of the company’s stock valued at $885,000 after acquiring an additional 1,762 shares during the last quarter. Tradition Wealth Management LLC boosted its stake in Evolus by 18.2% in the fourth quarter. Tradition Wealth Management LLC now owns 13,000 shares of the company’s stock valued at $144,000 after acquiring an additional 2,000 shares in the last quarter. Finally, MetLife Investment Management LLC grew its holdings in Evolus by 6.3% in the fourth quarter. MetLife Investment Management LLC now owns 34,272 shares of the company’s stock worth $378,000 after purchasing an additional 2,044 shares during the last quarter. Hedge funds and other institutional investors own 90.69% of the company’s stock.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.